Literature DB >> 27797825

MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer.

Federica Lo Sardo, Mattia Forcato1, Andrea Sacconi, Valeria Capaci2, Francesca Zanconato3, Silvia Di Agostino, Giannino Del Sal2,4, Pier Paolo Pandolfi5, Sabrina Strano6, Silvio Bicciato1, Giovanni Blandino.   

Abstract

Lung cancer is the first cause of cancer death worldwide and the Hippo pathway transcriptional coactivators YAP/TAZ have a pro-oncogenic role in this context. In order to understand the mechanisms through which YAP/TAZ elicit their oncogenic role in different systems, many studies are focused on YAP/TAZ target genes involved in the regulation of cell proliferation/survival and migration. However, there is scarce evidence on the role of YAP/TAZ in microRNA regulation while there is increasing evidence supporting the role of microRNAs in the main oncogenic processes. Here, we showed that YAP/TAZ were able to regulate several microRNAs in non-small cell lung cancer (NSCLC) cell lines. In detail, we focused on a cluster of three oncogenic microRNAs (miR-25, 93 and 106b) hosted in the MCM7 gene that were overexpressed in lung tumors compared to normal tissues. In addition, similar behavior was observed in breast cancer and head and neck tumor casuistries, where they showed a prognostic role. In NSCLC cells, YAP/TAZ induced the transcription of the MCM7 gene and its hosted miRs, thereby promoting cell proliferation through the post-transcriptional inhibition of the p21 cell cycle regulator. Accordingly, p21 was maintained at low levels in lung tumors compared to normal tissues. Conversely, its expression was restored in NSCLC cells upon YAP/TAZ interference or upon treatment with the statin cerivastatin. In summary, we provide evidence for a novel mechanism of modulation supporting the protumorigenic functions of the YAP/TAZ factors through the modulation of a bioncogenic locus consisting of one gene and three hosted microRNAs.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27797825      PMCID: PMC6276925          DOI: 10.1093/carcin/bgw110

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  50 in total

1.  Switch enhancers interpret TGF-β and Hippo signaling to control cell fate in human embryonic stem cells.

Authors:  Tobias A Beyer; Alexander Weiss; Yuliya Khomchuk; Kui Huang; Abiodun A Ogunjimi; Xaralabos Varelas; Jeffrey L Wrana
Journal:  Cell Rep       Date:  2013-12-12       Impact factor: 9.423

Review 2.  The MCM helicase: linking checkpoints to the replication fork.

Authors:  Susan L Forsburg
Journal:  Biochem Soc Trans       Date:  2008-02       Impact factor: 5.407

3.  Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer.

Authors:  Masaki Mori; Robinson Triboulet; Morvarid Mohseni; Karin Schlegelmilch; Kriti Shrestha; Fernando D Camargo; Richard I Gregory
Journal:  Cell       Date:  2014-02-27       Impact factor: 41.582

4.  Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation.

Authors:  Laura Poliseno; Leonardo Salmena; Luisa Riccardi; Alessandro Fornari; Min Sup Song; Robin M Hobbs; Paolo Sportoletti; Shorheh Varmeh; Ainara Egia; Giuseppe Fedele; Lucia Rameh; Massimo Loda; Pier Paolo Pandolfi
Journal:  Sci Signal       Date:  2010-04-13       Impact factor: 8.192

5.  The RUNX2 transcription factor cooperates with the YES-associated protein, YAP65, to promote cell transformation.

Authors:  Michele I Vitolo; Ian E Anglin; William M Mahoney; Keli J Renoud; Ronald B Gartenhaus; Kurtis E Bachman; Antonino Passaniti
Journal:  Cancer Biol Ther       Date:  2007-03-01       Impact factor: 4.742

6.  YAP mediates crosstalk between the Hippo and PI(3)K–TOR pathways by suppressing PTEN via miR-29.

Authors:  Karen Tumaneng; Karin Schlegelmilch; Ryan C Russell; Dean Yimlamai; Harihar Basnet; Navin Mahadevan; Julien Fitamant; Nabeel Bardeesy; Fernando D Camargo; Kun-Liang Guan
Journal:  Nat Cell Biol       Date:  2012-12       Impact factor: 28.824

7.  Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients.

Authors:  F Ganci; A Sacconi; N Bossel Ben-Moshe; V Manciocco; I Sperduti; L Strigari; R Covello; M Benevolo; E Pescarmona; E Domany; P Muti; S Strano; G Spriano; G Fontemaggi; G Blandino
Journal:  Ann Oncol       Date:  2013-10-09       Impact factor: 32.976

8.  LATS2 tumour specific mutations and down-regulation of the gene in non-small cell carcinoma.

Authors:  Mojca Strazisar; Vid Mlakar; Damjan Glavac
Journal:  Lung Cancer       Date:  2008-11-12       Impact factor: 5.705

9.  Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer.

Authors:  Gouji Toyokawa; Ken Masuda; Yataro Daigo; Hyun-Soo Cho; Masanori Yoshimatsu; Masashi Takawa; Shinya Hayami; Kazuhiro Maejima; Makoto Chino; Helen I Field; David E Neal; Eiju Tsuchiya; Bruce A J Ponder; Yoshihiko Maehara; Yusuke Nakamura; Ryuji Hamamoto
Journal:  Mol Cancer       Date:  2011-05-28       Impact factor: 27.401

10.  MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells.

Authors:  Cristian Taccioli; Giovanni Sorrentino; Alessandro Zannini; Jimmy Caroli; Domenico Beneventano; Laura Anderlucci; Marco Lolli; Silvio Bicciato; Giannino Del Sal
Journal:  Oncotarget       Date:  2015-11-17
View more
  24 in total

Review 1.  An overview of signaling pathways regulating YAP/TAZ activity.

Authors:  Boon Chin Heng; Xuehui Zhang; Dominique Aubel; Yunyang Bai; Xiaochan Li; Yan Wei; Martin Fussenegger; Xuliang Deng
Journal:  Cell Mol Life Sci       Date:  2020-08-03       Impact factor: 9.261

Review 2.  The interplay between noncoding RNA and YAP/TAZ signaling in cancers: molecular functions and mechanisms.

Authors:  Yirao Zhang; Yang Wang; Hao Ji; Jie Ding; Keming Wang
Journal:  J Exp Clin Cancer Res       Date:  2022-06-14

Review 3.  miR-106b as an emerging therapeutic target in cancer.

Authors:  Surendra Kumar Sagar
Journal:  Genes Dis       Date:  2021-02-12

4.  MicroRNA-106b Regulates Expression of the Tumour Suppressors p21 and TXNIP and Promotes Tumour Cell Proliferation in Mycosis Fungoides.

Authors:  Lise M Lindahl; Maria Gluud; Thomas Emmanuel; Emil A Thomsen; Tengpeng Hu; Anne H Rittig; Pamela Celis; Veronica Stolearenco; Thorbjørn Krejsgaard; Claus Johansen; Andreas Willerslev-Olsen; Terkild B Buus; Anders Woetmann; Lars Aagaard; Carsten Geisler; Thomas Litman; Jacob G Mikkelsen; Niels Odum; Lars Iversen
Journal:  Acta Derm Venereol       Date:  2020-09-30       Impact factor: 3.875

5.  MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis.

Authors:  Aline de Conti; Juliana Festa Ortega; Volodymyr Tryndyak; Kostiantyn Dreval; Fernando Salvador Moreno; Ivan Rusyn; Frederick A Beland; Igor P Pogribny
Journal:  Oncotarget       Date:  2017-08-01

Review 6.  Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.

Authors:  Maria Ferraiuolo; Lorena Verduci; Giovanni Blandino; Sabrina Strano
Journal:  Int J Mol Sci       Date:  2017-05-03       Impact factor: 5.923

Review 7.  [Role of Hippo Signaling Pathway in Lung Cancer].

Authors:  Yuechao Liu; Ying Xing; Li Cai
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-09-20

8.  MiR-93 inhibits the vascular calcification of chronic renal failure by suppression of Wnt/β-catenin pathway.

Authors:  Jun Peng; Chao Qin; Shu-Yan Tian; Jia-Qing Peng
Journal:  Int Urol Nephrol       Date:  2021-06-17       Impact factor: 2.370

9.  Clinical significance of YAP1 and TAZ in esophageal squamous cell carcinoma.

Authors:  Li Liu; Ziyang Lu; Xiayun Hu; Tianyuan Su; Liping Su; Hongwei Pu
Journal:  Medicine (Baltimore)       Date:  2021-07-16       Impact factor: 1.817

Review 10.  YAP/TAZ Activation as a Target for Treating Metastatic Cancer.

Authors:  Janine S A Warren; Yuxuan Xiao; John M Lamar
Journal:  Cancers (Basel)       Date:  2018-04-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.